Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma

OBJECTIVE: We aimed to investigate the cost-effectiveness of nivolumab plus chemotherapy and nivolumab plus ipilimumab versus chemotherapy in the first-line treatment for advanced esophageal squamous-cell carcinoma (ESCC) patients from a healthcare system perspective in China. METHODS: On the basis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shixian, Dou, Lei, Wang, Kaixuan, Shi, Zhao, Wang, Ruixue, Zhu, Xiaohong, Song, Zehua, Li, Shunping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353037/
https://www.ncbi.nlm.nih.gov/pubmed/35936686
http://dx.doi.org/10.3389/fonc.2022.899966

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353037/
https://www.ncbi.nlm.nih.gov/pubmed/35936686
http://dx.doi.org/10.3389/fonc.2022.899966

Ejemplares similares